Analysis about bDMARD drug survival in rheumatoid arthritis

Ingress-Health publishes analysis about bDMARD drug survival in rheumatoid arthritis Persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from ideal in rheumatoid arthritis (RA) patients. An Ingress-Health team analyzed in a German claims data study both drug survival and therapy switches with regard to 2nd line bDMARD therapy in RA patients. Analysis was based

Lees meer

Results of a retrospective claims data analysis on MTX therapy adherence and persistence

Ingress-health publishes results of a retrospective claims data analysis on MTX therapy adherence and persistence MTX therapy is the recommended first-line treatment in rheumatoid arthritis (RA). However, it was not known how RA patients adhere to MTX treatment recommendations and what their persistence to therapy is. Ingress-health explored these questions by a retrospective analysis of

Lees meer